Table 2.
microRNAs (miRNAs) associated with colorectal cancer (CRC) currently in clinical trials.
| Identifier | Status/phase | Study title | Disease/stages | Interventions |
|---|---|---|---|---|
| NCT04149613 | Unknown | Predictive and prognostic value of Inflammatory markers and microRNA in stage IV colorectal cancer | CRC/IV | |
| NCT03309722 | Recruiting | Molecular pathology of colorectal cancer: Investigating the role of novel molecular profiles, miRNAs, and their targets in colorectal cancer progression | CRC | Other: biomarker study |
| NCT01712958 | Unknown | Quantifying microRNA levels of colon | CRC | |
| NCT02364154 | Completed | Colorectal cancer detected by 1H NMR spectroscopy | CRC | Other: control group-blood sampling |
| NCT02402036 | Terminated/II | A biomarker study in patients getting regorafenib for metastatic colorectal cancer | Colon cancer | Drug: regorafenib |
| NCT01828918 | Unknown/I | Biomarkers for the early diagnosis, prediction, prognosis for colorectal cancers | CRC | Genetic: microRNAs |
| NCT04523389 | Recruiting | Contents of circulating extracellular vesicles: Biomarkers in colorectal cancer patients | CRC | Biological: analysis of circulating exosomes, size, and number |
| NCT04294953 | Unknown/II | Efficacy of perioperative duloxetine as a part of multimodal analgesia in laparoscopic colorectal cancer surgery | CRC | Drug: duloxetine |
| NCT01916239 | Completed/I, II, | Pomegranate extract supplementation in colorectal cancer patients | CRC | Dietary supplement: standard pomegranate extract formulation |
| NCT03362684 | Completed | PETACC-8 miR-31–3p and miR-31–5p ancillary study | CRC | Drug: Cetuximab, FOLFOX |
| NCT02876133 | Unknown | Narrow band imaging versus white light for colonoscopy serrate lesions detection | Colon cancer; colon sessile serrated adenoma/polyp | Device: narrow band imaging withdrawal, white light withdrawal |
NMR: nuclear magnetic resonance; FOLFOX: folinic acid, fluorouracil, and oxaliplatin.